← Leaderboards
Laura P. Hale
University Of Arizona
$6,508,905
Attributed
$7,191,135
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,191,135 · 12
By mechanism
P01$2,686,997 · 3
R21$2,561,770 · 7
R01$1,942,368 · 2
Top collaborators
- Joseph Turek4 shared
Most similar at University Of Arizona
Same institution · by research overlap
- Janko Nikolich-Zugich$55,130,377
- Bonnie Lafleur$4,152,807
- Jennifer L. Uhrlaub$823,770
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteProgramsMolecularProductionMouse ModelFlow CytometryMediatingThymic TissueThymus GlandCellsGene ExpressionTissuesInfectionBaseHuman TissueFoundationsMonitorIn VivoPathway InteractionsMolecular AnalysisInstitutionChronicCritical PathwaysHistologic
Grant awards (27)
Tolerance to Allogeneic Hearts via Implantation of Cultured Donor Thymus$725,892
R01 · FY2025 · HL
Human Target Verification and Thymic Function Core$364,891
P01 · FY2025 · AG · contact PI
Inducing Xenotolerance via Chimeric Thymus$195,819
R21 · FY2025 · AI · contact PI
Core C: Human Thymus Core$361,825
P01 · FY2024 · AI · contact PI
Transplantation of Cryopreserved Thymus$201,250
R21 · FY2024 · AI
Human Target Verification and Thymic Function Core$175,496
P01 · FY2024 · AG · contact PI
Core C: Human Thymus Core$489,293
P01 · FY2023 · AI · contact PI
Transplantation of Cryopreserved Thymus$241,500
R21 · FY2023 · AI
Human Target Verification and Thymic Function Core$183,168
P01 · FY2023 · AG · contact PI
Core C: Human Thymus Core$365,470
P01 · FY2022 · AI · contact PI
Core C: Human Thymus Core$365,884
P01 · FY2021 · AI · contact PI
Core C: Human Thymus Core$380,970
P01 · FY2020 · AI · contact PI
Mechanisms Underlying Colorectal Cancer Risk in IBD (PQ6)$160,494
R21 · FY2013 · CA · contact PI
Mechanisms Underlying Colorectal Cancer Risk in IBD (PQ6)$204,885
R21 · FY2012 · CA · contact PI
Chemoprevention of IBD-Associated Colon Cancer$241,983
R01 · FY2010 · CA · contact PI
Chemoprevention of IBD-Associated Colon Cancer$241,983
R01 · FY2009 · CA · contact PI
Chemoprevention of IBD-Associated Colon Cancer$241,983
R01 · FY2008 · CA · contact PI
Chemoprevention of IBD-Associated Colon Cancer$241,983
R01 · FY2007 · CA · contact PI
Mast Cells and IBD Pathogenesis$189,345
R21 · FY2007 · DK · contact PI
Chemoprevention of IBD-Associated Colon Cancer$248,544
R01 · FY2006 · CA · contact PI
Mast Cells and IBD Pathogenesis$233,318
R21 · FY2006 · DK · contact PI
Bromelain Proteinase Activity in IBD$173,739
R21 · FY2006 · AT · contact PI
Bromelain as a Biologically-Based Therapy for IBD$192,500
R21 · FY2005 · AT
Novel Oral Adjuvant for Dental Vaccines$192,500
R21 · FY2005 · DE
Bromelain Proteinase Activity in IBD$191,420
R21 · FY2005 · AT
Novel Oral Adjuvant for Dental Vaccines$192,500
R21 · FY2004 · DE
Bromelain as a Biologically-Based Therapy for IBD$192,500
R21 · FY2004 · AT